160 results about "Competitive binding" patented technology

A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples.

The invention relates to a latex enhanced immunoturbidimetry kit for the detection of asymmetric dimethylarginine content. Specifically, the invention relates to a latex enhanced immunoturbidimetry kit for the detection of asymmetric dimethylarginine (ADMA) content in human blood samples. The kit comprises a mouse anti-human monoclonal antibody solution, an ADMA-human Serum albumin complex crosslinked latex particle expansion and an ADMA calibrator. According to the method, by the utilization of competitive binding of free ADMA in blood and ADMA crosslinked on the surface of latex particles to ADMA monoclonal antibody, turbidity formed by the reaction between the ADMA-crosslinked latex particles and ADMA monoclonal antibody is reduced. Therefore, the content of ADMA is detected through the reduction degree of turbidity. The kit provided by the invention can be applied in a biochemical analyzer commonly-used in clinic, is convenient and rapid to operate and has strong specificity. Both sensitivity and detection range of the kit can satisfy clinic application needs.

The invention relates to a device for determining two or more respiratory parameters relating to an individual and a method for determining two or more respiratory parameters relating to an individual by means of the device. The disclosed device and method may be used in an individual suffering from pulmonary gas exchange problems relating to gas exchange of oxygen and/or carbon dioxide, e.g. a patient with chronic obstructive pulmonary disease. The device and method may also be used in a healthy individual or in an animal, e.g. for research experiments. The device has detection means for oxygen and carbon dioxide contents in inspired and expired gas and blood. The device is controlled by a computer with functionality for entering oxygenation, carbon dioxide and acid-base values from one or more blood samples from arterial, venous, central venous or mixed venous blood samples, and with the parameter estimation based on equations of gas exchange of both oxygen and carbon dioxide and equations describing the acid-base chemistry of blood potentially including the competitive binding of oxygen and carbon dioxide to hemoglobin.

The invention relates to a pesticide and veterinary drug multi-residue detection method based on a microarray detection chip. The method comprises the steps that a micromolecular pesticide and veterinary drug hapten is coupled with bovine serum albumin to prepare an immunizing antigen; a mouse is immunized by the immunizing antigen to prepare a corresponding pesticide and veterinary drug monoclonal antibody; a biochip sample application instrument for a monoclonal antibody acquisition probe performs sample application on an agarose modified slide solid phase carrier to prepare a multi-repeat monoclonal antibody acquisition probe microarray; the pesticide and veterinary drug hapten is coupled with ovalbumin to prepare a hapten-OVA (ovalbumin) couplet; a fluorescent molecule Cy3 is then used for labeling; sample liquid to be detected is incubated with the chip after mixed with a labeling detection antigen according to a certain concentration; a to-be-detected antigen in a sample and the corresponding labeling detection antigen are directly and competitively bound with the corresponding monoclonal antibody acquisition probe fixed on the chip; elution is performed under a certain condition; and a result is detected by a biochip scanner. The method can detect multiple pesticide and veterinary drug residues in the subsidiary agricultural product sample simultaneously, and is applicable to high-throughput, quick and accurate detection of drug residues in planting and culture production.

The invention provides a method of detecting surrogate markers for active tuberculosis in a serum sample. The surrogate markers are selected from serum mycolic acid antigen, serum anti-mycolic acid antibodies or both. The method includes the steps of combining the serum sample with a labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acids to produce a combined serum sample, the antibody or fragment thereof not substantially cross-reacting with cholesterol and the label being selected so that binding of the labelled antibody to immobilized mycolic acid antigen of mycobacterial origin produces a detectable signal and combining a blank sample with the labelled monoclonal immunoglobulin antibody or fragment thereof to mycolic acid to produce a combined blank sample. The method includes exposing both samples to immobilised mycolic acid antigen of mycobacterial origin or a synthetic analogue or analogues thereof so that the labelled immunoglobulin antibodies or fragments thereof in each sample bind to the immobilised antigen to produce detectable signals. If the surrogate markers are present, the signal produced by the blank sample will be stronger than that produced by the serum sample because of inhibition of binding of the labelled antibody in the serum sample arising from prior binding of the labelled antibody with the mycolic acid antigen in the serum sample or by competitive binding of serum anti-mycolic acid antibodies in the serum sample to the immobilised mycolic acid antigen or both.

The invention provides a high-sensitivity chemiluminescence immunoassay kit, and a preparation method and application thereof, belonging to the technical field of clinical immunoassay. The high-sensitivity chemiluminescence immunoassay kit comprises a solid-phase vector directly coated with a capture molecule, a biotin-labeled marker molecule and luminescent substance-labeled streptavidin, whereinthe marker molecule is capable of binding to a target analyte in a to-be-detected sample, and the capture molecule is capable of specifically binding to the target analyte in the to-be-detected sample or is an analog of the target analyte in the to-be-detected sample; or the marker molecule is capable of competitively binding to the target analyte in the to-be-detected sample, and the capture molecule is capable of specifically binding to the target analyte in the to-be-detected sample. The kit provided by the invention is based on the structural characteristics of streptavidin; per mole of tetramer molecules can bind to four moles of biotin molecules, and strong affinity are formed between the tetramer molecules and the biotin molecules; and a cyclic amplification reaction process is constructed to realize signal amplification, so the sensitivity of the kit is improved.

The invention discloses a method for detecting the affinity of monoclonal antibodies of transmembrane proteins. The method mainly includes steps of 1), constructing stable cell strains with membrane protein high expression to guarantee the maximum right shift of positive combination peaks in FACS (fluorescence-activated cell sorter) assay; 2), labeling antibodies by the aid of fluorecein; 3), carrying out saturation binding assay; 4), carrying out competitive binding assay; 5), processing data. The method has the advantages that the affinity of the monoclonal antibodies of the transmembrane proteins can be effectively measured; radioactive isotopes can be omitted, accordingly, the method is high in safety and sensitivity and good in repeatability, stable and reliable detection results can be obtained, and the like.

The invention discloses a method for improving the structural stability of a biological material and the biological material. The method comprises the steps of soaking the biological material in an aqueous solution of tea polyphenol and metal ions, and adsorbing the tea polyphenol on hydrophobic sections of elastin fibers under the function of hydrogen bonds. In this way, the structural stabilityof elastin is improved, the metal ions and calcium ions conduct competitive binding to adsorb the tea polyphenol, and thus the calcification of the biological material is inhibited. By means of the method, the structural stability and anti-calcification performance of the biological material can be improved, and the service life of the biological material is potentially prolonged.

The invention discloses a method for detecting tetracycline (TET) based on a colloidal gold (AuNPs) chromatography test strip of aptamer. The method uses specific binding between colloidal gold and the aptamer and competitive binding capacity strength between the tetracycline and DNA (deoxyribonucleic acid) and the aptamer. The method comprises the following steps of synthesizing colloidal gold nanoparticles suitable for marking the aptamer; assembling and coupling the colloidal gold and the aptamer; assembling streptavidin with a DNA chain; preprocessing a sample pad and a gold pad; scribing lines on an NC membrane; assembling the test strip; detecting standard tetracycline; performing selectivity and specificity experiments; using the established colloidal gold test strip based on the aptamer to measure the tetracycline in a practical sample. The tetracycline detecting method provided by the invention has the advantages of having better selectivity and flexibility, being simple, economic and easy to operate and being more suitable for in-site quick detection.

The present invention provides for an assay that identifies kinase inhibitors by employing fluorescence resonance energy transfer in a competition binding approach.

A competitive binding assay is used to determine whether a non-nucleic acid molecule from a library of non-nucleic acid molecules binds to a target. The non-nucleic acid molecule competes with a labeled nucleic acid ligand for binding to the target which may be immobilized. Detecting displacement of labeled nucleic acid ligand from a complex of the labeled nucleic acid ligand and the target determines binding of the non-nucleic acid molecule to the target. The nucleic acid ligand may be immobilized and contacted with a labeled target to form a complex. Adding a non-nucleic acid molecule to the complex displaces labeled target from the complex, and detecting displacement of the labeled target determines binding of the non-nucleic acid molecule to the target. Labeled nucleic acid ligand or labeled target displaced from or remaining in the complex can be detected for detecting displacement. Nucleic acid ligands that bind to the target are identified by the SELEX method. The assay provides a high throughput screening method for determining whether a non-nucleic acid molecule binds to a target.

The invention discloses a candida mannan antigen immunoassay kit, comprising a Mn-coated ELISA plate and an anti-Mn polyclonal enzyme-labeled antibody. According to the kit of the invention, the ELISA plate is coated with Mn, a sample or standard antigen to be detected and a coating antigen are subjected to competitive binding with a limited antibody binding site and then to rendering reaction via horse radish peroxidase and a substrate, a standard curve is drawn according to an Mn standard article, and concentration value of the antigen to be detected is calculated according to the standard curve. The kit of the invention has good sensitivity and specificity, results show high accordance rate with a reference reagent, more accurate and more reliable detection results can be provided, the kit is simple and easy to operate, detecting is fast and sensitive, an ELISA apparatus used herein is simple and popular and is low in cost, and the kit of the invention is an effective tool for quantitative detection of Mn.